中药黄芩具有明确的抗肝癌药理活性，发掘其抗肝癌药效物质和作用靶标是医药生物学领域的研究热点。项目组前期发现黄芩中能够通过抑制PDGFRβ发挥抗肝癌活性，然而，黄芩中哪些组分能够靶向PDGFRβ发挥抗肝癌活性仍不清楚，是本项目拟解决的关键科学问题。本项目拟发展基于膜蛋白无细胞合成技术的生物色谱新方法，实现PDGFRβ在色谱固定相上的大量表达及天然活性构象的维持。通过建立PDGFRβ微型生物色谱技术新方法筛选黄芩中PDGFRβ的亲和活性组分，并采用生物色谱竞争、表面等离子共振等手段，在细胞和分子水平探讨活性化合物与PDGFRβ的相互作用关系，评价亲和组分的体内体外抗肝癌活性并探索其作用机制。通过本项目的开展，以期进一步阐明黄芩抗肝癌的药效物质基础，有望为肝癌治疗提供新的候选先导化合物，发展的新型基于膜蛋白无细胞合成技术的生物色谱新方法也可为中药活性成分的筛选提供新的思路与技术手段。

Scutellariae Radix has definite anti-hepatoma pharmacological activity, and it is a hotspot in the field of medical biology to explore its pharmacodynamic basis and targets. In the preliminary work of our project team, it was found that Scutellariae Radix can exert its anti-hepatoma activity by inhibiting PDGFRβ. However, it is still unclear which components of Scutellariae Radix can target PDGFRβ to exert its anti-hepatoma activity, which is the key scientific problem to be solved in this project. So this project plans to develop a new method of biochromatography based on membrane protein cell-free synthesis technology to achieve the high expression and maintenance of natural active conformation of PDGFRβ on chromatography stationary phase. The affinity active components of PDGFRβ in Scutellariae Radix were screened by establishing a new method of micro biological chromatography, and the interaction between the active compounds and PDGFRβ was studied at the cellular and molecular level by means of biological chromatography competition, surface plasmon resonance and so on. The anti-hepatoma activity of the affinity components in vitro and in vivo was evaluated and the mechanism was explored. Through the development of this project, we hope to further clarify the pharmacodynamic basis of Scutellariae Radix for anti-hepatoma, and provide new candidate lead compounds for the treatment of hepatoma. What’s more, the new biochromatography method based on membrane protein cell-free synthesis technology can also provide a new idea and means for the screening of active components of traditional Chinese medicine.